An ␣ 4 ␤ 1 /␣ 4 ␤ 7 dual antagonist, 35 S-compound 1, was used as a model ligand to study the effect of divalent cations on the activation state and ligand binding properties of ␣ 4 integrins. In the presence of 1 mM each Ca 2ϩ /Mg 2ϩ , 35 S-compound 1 bound to several cell lines expressing both ␣ 4 ␤ 1 and 
primarily ␣ 4 ␤ 1 with a K D of 18 nM. In contrast, the binding of 35 S-compound 1 to Mn 2ϩ -activated Jurkat cells occurred slowly, reaching equilibrium by 60 min, and failed to dissociate within another 60 min. The ability of four ␣ 4 ␤ 1 /␣ 4 ␤ 7 antagonists to block binding of activated ␣ 4 ␤ 1 or ␣ 4 ␤ 7 to vascular cell adhesion molecule-1 or mucosal addressin cell adhesion molecule-1, respectively, or to 35 S-compound 1 was measured, and a similar rank order of potency was observed for native ligand and probe. Inhibition of 35 S-compound 1 binding to ␣ 4 ␤ 1 in Ca 2ϩ /Mg 2ϩ was used to identify nonselective antagonists among these four. These studies demonstrate that ␣ 4 ␤ 1 and ␣ 4 ␤ 7 have distinct binding properties for the same ligand, and binding parameters are dependent on the state of integrin activation in response to different divalent cations.
Lymphocyte recruitment in the vasculature is regulated by the differential expression and activation of homing receptors (selectins and integrins) on lymphocytes that interact with counter-receptors of the Ig superfamily on endothelial cells. This interaction mediates a multistep process, involving rolling and tethering of leukocytes to endothelial ligands, rapid activation of integrins by locally released chemokines, stable adhesion of activated integrins to endothelial ligands, and transendothelial migration through the vessel wall . Although all integrins expressed on leukocytes can mediate firm adhesion during normal lymphocyte trafficking and in response to inflammatory stimuli, ␣ 4 ␤ 1 and ␣ 4 ␤ 7 are members of a small subset of integrins that can also mediate rolling Berlin et al., 1995) . In vivo studies with monoclonal antibodies or inhibitory peptides demonstrate the pathophysiological role of ␣ 4 ␤ 1 and ␣ 4 ␤ 7 in leukocyte-mediated inflammation in animal models (Foster, 1996; Butcher, 1999) , and clinical trials with Antegren (anti-␣ 4 , Elan/Biogen) resulted in remission for Crohn's disease patients (Gordon et al., 2001) .
␣ 4 integrins are constitutively expressed on a variety of leukocytes and can bind to shared or distinct binding partners. ␣ 4 ␤ 1 is expressed on lymphocytes, eosinophils, and monocytes and mediates adhesion to vascular cell adhesion molecule-1 (VCAM-1) expressed on the endothelium and to the connecting segment-1 (CS-1) subdomain of human fibronectin in the extracellular matrix. ␣ 4 ␤ 1 and ␣ 4 ␤ 7 are coexpressed on peripheral blood leukocytes, and ␣ 4 ␤ 7 is highly expressed on a discrete subpopulation of gut-homing memory T and B lymphocytes, mediating lymphocyte adhesion within the vasculature of the gastrointestinal tract, where its major ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), is preferentially expressed on high endothelial venules (Butcher, 1999) . Although both ␣ 4 ␤ 7 and ␣ 4 ␤ 1 can bind VCAM-1 and CS-1, ␣ 4 ␤ 1 does not bind MAd-CAM-1, and ␣ 4 ␤ 7 binds to MAdCAM-1 with higher affinity than to VCAM-1 or to CS-1 (Berlin et al., 1993) .
Key motifs for the binding of ␣ 4 ␤ 7 and ␣ 4 ␤ 1 to native ligands have been defined as leucine-aspartic acid-threonine in MAdCAM-1 (Viney et al., 1996) , isoleucine-aspartic acidserine in VCAM-1 (Wang et al., 1995) , and leucin-aspartic acid-valine in CS-1 (Wayner and Kovach, 1992) . Small molecule antagonists of ␣ 4 ␤ 7 that mimic the LDT motif have been described that block the binding of ␣ 4 ␤ 7 -expressing cells to MAdCAM-Ig in the presence of Mn 2ϩ (Carson et al., 1997; Shroff et al., 1998; Martin et al., 1999; Harriman et al., 2000; Egger et al., 2002) . Similarly, antagonists of ␣ 4 ␤ 1 have been reported to block binding of Mn 2ϩ -activated (Jackson et al., 1997; Vanderslice et al., 1997; Lin et al., 1998; Hagmann et al., 2001; Muller et al., 2001 ) and unactivated ␣ 4 ␤ 1 (Chen et al., 1999 ) to ligand in vitro.
The essential role of cation-binding sites in regulating integrin function is known, but the coordination of each cationbinding site and the individual role of different metal cations is not well understood (Leitinger et al., 2000) . All integrin ␣-subunits have seven homologous 60-amino acid repeats at the N terminus that have been predicted to fold into a ␤-propeller structure (Shimaoka et al., 2002) , and three to four putative Ca 2ϩ binding sites are located within repeats 4 through 7. A metal ion-dependent activation site motif is a unique Mg 2ϩ /Mn 2ϩ binding site located in the I-domain of the ␣-subunit, and divalent cation bound at this site has a structural role in coordinating the binding of ligand to the I-domain containing integrins. Although ␣ 4 does not contain an I-domain, an I-like domain that contains a metal iondependent activation site-like motif is present in the ␤-chain of all integrins. Although the effect of divalent cations on ␣ 4 ␤ 7 -ligand interactions has not been extensively characterized, recent studies have shown that Ca 2ϩ is essential to support rolling under shear flow, whereas Mg 2ϩ can promote firm adhesion of cells expressing ␣ 4 ␤ 7 to MAdCAM-1 (de Chateau et al., 2001) .
To assess the effect of divalent cations on the activation state of ␣ 4 integrins expressed on human lymphocytes, we used a novel dual ␣ 4 ␤ 1 /␣ 4 ␤ 7 antagonist, 35 S-compound 1 (Fig.  1 ), as a model ligand. A similar approach has been used to study multiple activation states of ␣ 4 ␤ 1 through their different affinities for a small molecule ligand (Chen et al., 1999 , but the binding of a small molecule ligand to different activation states of ␣ 4 b 7 has not been described. These studies provide new information that ␣ 4 ␤ 1 and ␣ 4 ␤ 7 have distinct binding affinities for the same small molecule ligand, and binding is dependent on the state of integrin activation in response to different divalent cations.
Materials and Methods
Compounds. Compound 1, and compound 4, N-{[N-(3,5-dichlorobenzenesulfonyl) ]-2(R)-methylprolyl}-(D)-phenylalanine, were synthesized as described previously (Hagmann et al., 2001; Kopka et al., 2002; or by using similar methods. TR14035, N-(2,6-dichlorobenzoyl)-(L)-4-(2Ј,6Ј-bis-methoxyphenyl) phenylalanine, was synthesized as described previously (Sircar et al., 1999a) 
-butyric acid, was synthesized as described previously . The structures of all compounds are shown in Fig. 1 S-compound 1 was purified by semipreparative HPLC and formulated as a solution in methanol with a concentration of 1.14 mCi/ml. The radiochemical purity of the compound was Ͼ95% as measured by reverse phase HPLC, and the specific activity was measured to be 722 Ci/mmol by liquid chromatography/ mass spectrometry. The radioligand in MeOH was aliquoted and stored at Ϫ20°C. The binding affinity for the radiolabeled compound was indistinguishable from that of the unlabeled compound as measured by the ability of compound to block the binding of native ligands to cells expressing ␣ 4 ␤ 7 and ␣ 4 ␤ 1 .
Antibodies and Cell Lines. The following purified monoclonal antibodies were obtained from BD PharMingen (San Diego, CA): 4B4 (mouse anti-human ␤ 1 ), FIB27 (rat anti-mouse ␤ 7 that cross-reacts with human ␤ 7 ), and isotype controls (mouse IgG1, rat IgG2b). HP2/1 (mouse anti-human ␣ 4 ) was obtained from Coulter/Immunotech (Hialeah, FL). The following cell lines were used: RPMI-8866 cells (human B cell line) obtained from John A. Wilkins (University of Fig. 1 . Structure of antagonists of ␣ 4 ␤ 1 / ␣ 4 ␤ 7 integrins. The structures of compounds 1, 2, 3, and 4 (Hagmann et al., 2001; Kopka et al., 2002; Lin et al., 2002) , TR14035 (Sircar et al., 1999a) , and BIO7662 ) are shown. Chemical names are given in "Compounds".
Manitoba, Winnipeg, Canada); Jurkat and HUT-78 (human T cell lines) from American Type Culture Collection (Manassas, VA); and K562/␣ 4 ␤ 7 cells, a stably transfected human erythroleukemia cellline obtained from David J. Erle (University of California, San Francisco, San Francisco, CA).
Binding of Native Ligands to Cells Expressing ␣ 4 ␤ 7 and ␣ 4 ␤ 1 . A ligand binding assay for Mn 2ϩ -activated ␣ 4 ␤ 7 has been described previously and was performed by incubating RPMI-8866 cells (7.5 ϫ 10 5 cells/well) with Ͻ200 pM iodinated human MAdCAM-Ig. Similarly, a ligand binding assay for activated ␣ 4 ␤ 1 was performed by incubating Jurkat cells (5 ϫ 10 5 cells/well) expressing ␣ 4 ␤ 1 with Ͻ100 pM iodinated VCAM-Ig in the presence of Mn 2ϩ , as described previously (Hagmann et al., 2001 ). Purified VCAM-Ig and MAdCAM-Ig were labeled with 125 I using Bolton Hunter reagent and purified using HPLC gel filtration chromatography, and specific radioactivities were in excess of 1,100 Ci/mmol. Compounds were evaluated by incubating radioligand, compound (prepared in DMSO; Ͻ1% DMSO final concentration), cells, and binding buffer (25 mM HEPES, 150 mM NaCl, 3 mM KCl, 2 mM glucose, and 0.1% bovine serum albumin, pH 7.4) containing 1 mM MnCl 2 at 25°C for 30 min (␣ 4 ␤ 1 assays) or 45 min (␣ 4 ␤ 7 assays) in a 96-well Millipore (Bedford, MA) multiscreen MHVBN filtration plate. After filtration and a single wash with binding buffer, the filtration plates were dried and transferred to adaptor plates. After adding 100 l of Microscint-20 (PerkinElmer Life Sciences, Boston, MA) to each well, the plates were sealed, placed on a shaker for 1 min, and counted on a PerkinElmer Top-Count. Wells containing cells ϩ radioligand ϩ 1 M compound or DMSO alone served as controls to calculate 100 and 0% inhibition, respectively. , to selectively block ␣ 4 ␤ 1 . The cells were pelleted by centrifugation at 20,000g for 3 min, washed twice with binding buffer at 4°C, transferred to a scintillation vial containing 5 ml of CytoScint (ICN Pharmaceuticals, Costa Mesa, CA), and cell-associated 35 S-compound 1 was measured by scintillation counting. Tubes containing cells ϩ radioligand ϩ 1 M compound 1 or DMSO alone served as controls to calculate 100 and 0% inhibition, respectively. Data were analyzed by nonlinear regression to calculate B max and K D values.
Binding of a Dual
Kinetic analysis of 35 S-compound 1 binding to cells expressing ␣ 4 was performed by incubating RPMI-8866 cells (7.5 ϫ 10 5 cells/tube) expressing ␣ 4 ␤ 7 or Jurkat cells (5 ϫ 10 5 cells/tube) expressing ␣ 4 ␤ 1 in binding buffer containing either 1 mM MnCl 2 or 1 mM CaCl 2 and 1 mM MgCl 2 with 6.5 nM 35 S-compound 1 and 5 nM unlabeled compound 1 in siliconized Eppendorf microfuge tubes for 2 to 120 min at 4°C. RPMI-8866 cells were pretreated with 100 nM BIO7662 as described above. Binding was terminated by adding 5 M compound 1 at each time point. Cells were immediately transferred to an ice-bath for 10 min, pelleted by centrifugation at 20,000g for 3 min, and cell associated 35 S-compound 1 was determined by scintillation counting as described above.
When the rate of 35 S-compound 1 dissociation was evaluated, reaction mixtures were incubated with 6.5 nM 35 S-compound 1 and 5 nM unlabeled compound 1 for 1 h at 4°C, followed by the addition of 5 M compound 1 for another 2 to 120 min. as described above. Test compounds were evaluated by incubating radioligand, compound, cells, and binding buffer at 25°C for 45 min in a 96-well multiscreen filtration plate on a shaking platform. After filtration and a single wash with binding buffer containing either 1 mM MnCl 2 or 1 mM CaCl 2 and 1 mM MgCl 2 , the plates were processed and counted as described above for the binding of native ligand to cells expressing ␣ 4 . Nonspecific binding (NSB) was determined by the addition of 1 M compound 1.
Quantitative FACS Analysis. A total of 10 6 RPMI-8866 or Jurkat cells were incubated for 30 min on ice in FACS buffer (phosphate-buffered saline containing 1 mM each CaCl 2 and MgCl 2 , 5% fetal bovine serum, 100 g/ml goat IgG, and 0.05% sodium azide) containing saturating levels of the following phycoerythrin-conjugated antibodies: FIB504 rat anti-mouse ␤ 7 (2.4 g/ml; cross-reacts with human ␤ 7 ), MAR4 mouse anti-human ␤ 1 (80 g/ml), 9F10 mouse anti-human ␣ 4 (10 g/ml), mIgG1 isotype, and rIgG2a isotype controls. All phycoerythrin-conjugated antibodies were obtained from BD PharMingen. Cells were washed in FACS buffer and resuspended in FACS buffer containing 1 g/ml propidium iodide. Cells were analyzed by a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ). Standardized quantum R-phycoerythrin microbeads (Flow Cytometry Standards Corp., Fishers, IN) were analyzed by flow cytometry and used to create a calibration curve that relates mean fluorescence intensities to molecules of equivalent soluble fluorescence for use in calculating receptor density values.
Statistical Analysis. Curve fits and statistics were performed using KaleidaGraph (Synergy, Reading, PA) and GraphPad Prism (GraphPad Software Inc., San Diego, CA) with a one-way analysis of variance (nonparametric test) followed by a Tukey's post test if overall P Ͻ 0.05, and a paired t test was used when comparing only two sets of data. Data were analyzed by nonlinear regression with an equation for one-site binding to calculate B max and K D values. Nonlinear regression analysis was used with equations for one-phase exponential association with no weighting or one-phase exponential decay with no weighting to obtain curve fits for association and dissociation plots, respectively. R 2 values were used as an indication of the goodness of fit, and both single-and double-phase exponential equations were compared to obtain the best fit. Double reciprocal plots were analyzed by linear regression analysis.
Results
Potency of Compound 1 in ␣ 4 ␤ 1 and ␣ 4 ␤ 7 Ligand Binding Assays. Compound 1 (Fig. 1 ) represents one of a structural class of potent ␣ 4 ␤ 1 antagonists (Hagmann et al., 2001) . To determine whether compound 1 could also block ligand binding to ␣ 4 ␤ 7 , the ability of this compound to inhibit binding of 125 I-hMAdCAM-Ig to RPMI-8866 cells in the presence of the divalent cation Mn 2ϩ was evaluated using methods described previously . RPMI-8866 cells, a human B cell line, were chosen for the assay, because they express high levels of ␣ 4 ␤ 7 (ϳ60,000 ␣ 4 ␤ 7 receptors/cell), but low levels of ␣ 4 ␤ 1 (ϳ4,000 ␣ 4 ␤ 1 receptors/cell), as demonstrated by quantitative flow cytometry ( Fig. 2A) . In addition, the specificity of MAdCAM-Ig binding to ␣ 4 ␤ 7 on the RPMI-8866 cells has been confirmed by demonstrating that Dual Antagonist Binds Unactivated ␣ 4 ␤ 1 and Activated ␣ 4 ␤ 7 905 anti-␣ 4 and anti-␤ 7 mAbs block binding, whereas an anti-␤ 1 mAb does not block binding . Furthermore, the low levels of ␣ 4 ␤ 1 expressed on the RPMI-8866 cell line do not bind VCAM-Ig in the presence of anti-␤ 7 mAbs and 1 mM Mn 2ϩ or 1 mM Ca 2ϩ /Mg 2ϩ (data not shown). Thus, RPMI-8866 cells can be used to evaluate the potency of compounds in blocking binding of ␣ 4 ␤ 7 , but not ␣ 4 ␤ 1 , to MAd-CAM-Ig. Compound 1 inhibited the binding of MAdCAM-Ig to ␣ 4 ␤ 7 with an IC 50 of 1.1 nM (Table 1) .
To compare the potency of compound 1 for blockade of ␣ 4 ␤ 1 under similar conditions, the ability of the compound to inhibit 125 I-hVCAM-Ig binding to Jurkat cells expressing ␣ 4 ␤ 1 in the presence of the divalent cation Mn 2ϩ was performed as described previously . For this assay, Jurkat cells, a human T cell line, were chosen, because they express high levels of ␣ 4 ␤ 1 (ϳ90,000 ␣ 4 ␤ 1 receptors/cell), but low levels of ␣ 4 ␤ 7 (ϳ7,000 ␣ 4 ␤ 7 receptors/cell) (Fig. 2B) . Specificity of VCAM-Ig binding to ␣ 4 ␤ 1 on Jurkat cells, was confirmed previously using anti-␣ 4 and anti-␤ 1 mAbs to completely abrogate binding, in the absence of inhibition by anti-␤ 7 mAb (Fig. 3) . In the presence of 1 mM Mn 2ϩ , RPMI-8866 cells bound 35 S-compound 1 with a ratio of specific to nonspecific binding of 12 (Fig. 3A) . In the presence of 1 mM Ca 2ϩ /Mg 2ϩ , 35 S-compound 1 bound RPMI-8866 cells with a ratio of specific to nonspecific binding of 6. Specific binding was not observed in the presence of either 1 mM Ca 2ϩ or 1 mM Mg 2ϩ alone (data not shown). The inclusion of 10 mM EDTA in the binding reaction abrogated specific binding, as expected.
To determine whether the low level of ␣ 4 ␤ 1 present on RPMI-8866 cells ( Fig. 2A) contributed to the observed binding of 35 S-compound 1, binding was measured with or without 100 nM BIO7662 added to specifically block ␣ 4 ␤ 1 (Fig.  3A) . BIO7662, a highly selective inhibitor of ␣ 4 ␤ 1 Pepinsky et al., 2002; Leone et al., 2003) , was used for these studies because none of the available anti-␣ 4 or anti-␤ 1 neutralizing monoclonal antibodies blocked the binding of 35 S-compound 1 to ␣ 4 ␤ 1 even at concentrations up to 3.3 g/ml (data not shown). BIO7662 (100 nM) was selected to completely saturate ␣ 4 ␤ 1 (IC 50 of 0.03 nM in the ␣ 4 ␤ 1 / 125 I-VCAM-Ig binding assay; To determine whether the inability of 35 S-compound 1 to bind unactivated ␣ 4 ␤ 7 was dependent on cell type, we measured binding to K562 cells stably transfected with ␣ 4 ␤ 7 (K562/␣ 4 ␤ 7 ) in the presence of different divalent cations. As demonstrated by quantitative FACS analysis, K562/␣ 4 ␤ 7 cells express ϳ200,000 copies/cell of ␣ 4 ␤ 1 and ϳ200,000 copies/cell of ␣ 4 ␤ 7 (data not shown). In the presence of 1 mM Mn 2ϩ and 100 nM BIO7662, K562/␣ 4 ␤ 7 cells bound 35 Scompound 1 with a 19-fold ratio of specific to nonspecific binding, and binding was reduced by 63% compared with cells not treated with BIO7662 (Fig. 3B) . Thus, the binding of 35 S-compound 1 to activated K562/␣ 4 ␤ 7 cells is mediated by both ␣ 4 ␤ 1 and ␣ 4 ␤ 7 , with each integrin having a similar contribution to the total binding. In the presence of 1 mM Ca 2ϩ /Mg 2ϩ , 35 S-compound 1 bound K562/␣ 4 ␤ 7 cells with a ratio of specific to nonspecific binding of 31-fold (Fig. 3B) , but pretreating the cells with 100 nM BIO7662 abrogated binding (Fig. 3B) , indicating that K562/␣ 4 ␤ 7 cell binding to 35 Scompound 1 is mediated solely by unactivated ␣ 4 ␤ 1 . To extend the above-mentioned findings to another cell line, the effect of divalent cations on the binding of 35 S-compound to HUT-78 cells was evaluated. By FACS analysis, HUT-78 cells express equal proportions of both ␣ 4 ␤ 1 and ␣ 4 ␤ 7 (data not shown), and the relative receptor density of ␣ 4 ␤ 7 was similar to levels observed on RPMI-8866 cells (Erle et al., 1994) . Mn 2ϩ -activated HUT-78 cells bound to 35 S-compound 1 with a 10-or 2-fold ratio of specific to nonspecific binding in the absence or presence of 100 nM BIO7662, respectively (Fig. 3C) . In the presence of 1 mM Ca 2ϩ /Mg 2ϩ , 35 S-compound 1 bound unactivated HUT-78 cells with a ratio of specific to nonspecific binding of 9-fold, but failed to bind unactivated cells after pretreatment with 100 nM BIO7662 (Fig. 3C) , indicating that unactivated ␣ 4 ␤ 1 is also completely responsible for HUT-78 cell binding to 35 S-compound 1. Thus, the binding properties of 35 S-compound 1 for different activation states of ␣ 4 are not dependent on cell type or expression levels of ␣ 4 ␤ 1 relative to ␣ 4 ␤ 7 , but rather are dependent on the activation state of the integrins.
Binding Kinetics of 35 S-Compound 1 to RPMI-8866 Cells. After three cell lines expressing both ␣ 4 ␤ 1 and ␣ 4 ␤ 7 were evaluated, subsequent studies on ␣ 4 ␤ 7 focused on characterizing the binding of 35 S-compound 1 to RPMI-8866 cells that predominantly express ␣ 4 ␤ 7 . To determine whether an assay could be developed to study both the association and dissociation of unlabeled compounds from binding to activated ␣ 4 ␤ 7 , equilibrium and kinetic studies for the binding of 35 S-compound 1 to ␣ 4 ␤ 7 were performed in the presence of Mn 2ϩ with cells pretreated with 100 nM BIO7662 (Fig. 4) . in the absence (f) or presence (Ⅺ) of 100 nM BIO7662. Total binding was determined as described above, and treatment with 1 M unlabeled compound 1 was used to define NSB for cells treated with binding buffer alone (_) or binding buffer containing BIO7662 (u). Statistics were generated with Prism by using a one-way analysis of variance (nonparametric test) with a Tukey's post test, and ‫,ء‬ P Ͻ 0.001 when comparing total binding for each condition with the matched nonspecific binding control. The data represent the mean Ϯ S.E.M. calculated from a total of four replicates from at least two independent experiments. 
Dual Antagonist Binds Unactivated
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Binding of 35 S-compound 1 was dose-dependent and saturable with maximal binding to ␣ 4 ␤ 7 observed at approximately 10 nM. Assuming that each receptor bound one ligand, specific counts bound at saturation provided a direct measure of ␣ 4 ␤ 7 expression levels. Based on the calculation of B max values, the RPMI-8866 cells used in these studies had approximately 43,000 copies of ␣ 4 ␤ 7 /cell, which is in good agreement with the receptor density determined by quantitative FACS analysis ( Fig. 2A) .
The quadratic shape of the binding curve in Fig. 4 suggested that the apparent K D for binding was small compared with the concentration of ␣ 4 ␤ 7 (360 pM) present in the binding assay, which is consistent with reports that measure binding of small molecule antagonists to ␣ 4 ␤ 1 (Chen et al., 1999 ). Based on this observation, it was evident that the saturation binding curves measured titration of the receptor to full occupancy, and a kinetic assessment of affinity was used to measure actual affinity constants. In the presence of 1 mM Mn 2ϩ and 100 nM BIO7662, binding occurred rapidly with a k on of 0.05 nM Ϫ1 min Ϫ1 , reached equilibrium within 10 min, and reversed with a k off of 0.09 min Ϫ1 (Fig. 5 ). Thus, a K D value of 1.9 nM was calculated based on the binding kinetics of compound 1 to activated ␣ 4 ␤ 7 .
Effect of Divalent Cation Concentration on the Binding of 35 S-Compound 1 to RPMI-8866 Cells. To elucidate the role of divalent cations on integrin activation, the effects of metal ion concentration on the binding of the 35 S-compound 1 to RPMI-8866 cells were examined. Cells were pretreated with 100 nM BIO7662 to block ␣ 4 ␤ 1 , and binding was measured as a function of changing Mn 2ϩ or Mg 2ϩ concentrations from 0.03 to 100 mM (Fig. 6A) . Mn 2ϩ enhanced the binding of the 35 S-compound 1 to RPMI-8866 cells with an EC 50 of 0.5 mM, whereas Mg 2ϩ only enhanced binding at higher concentrations (3-fold increase in specific binding at 5 mM; Fig. 6A ). ␣ 4 ␤ 1 was determined by direct competition with unlabeled compound 1 at 1 M. Specific counts bound at saturation provided a direct measure of ␣ 4 ␤ 1 expression levels, and, based on this value, Jurkat cells used in these studies have approximately 64,000 copies (in Mn 2ϩ ) and 57,000 copies (in Ca 2ϩ /Mg 2ϩ ) of ␣ 4 ␤ 1 /cell, which is in agreement with the receptor density determined by quantitative FACS analysis (Fig. 2B) . Binding was dependent on the presence of divalent cations, and was blocked in the presence of 10 mM EDTA (data not shown).
As observed for the binding of 35 S-compound 1 to ␣ 4 ␤ 7 , the apparent K D for binding seemed to be small compared with the concentration of ␣ 4 ␤ 1 (350 and 320 pM, respectively) present in the binding assay (Fig. 7) . The kinetic assessment of binding of compound 1 to ␣ 4 ␤ 1 in the presence of 1 mM Mn 2ϩ indicated that binding occurred very slowly, reaching equilibrium by 60 min, and dissociation was not observed after another 60 min of incubation (Fig. 8A) , or even after another 180 min (48,036 specific cpm bound after 240 min of total incubation time; data not shown). In the presence of 1 mM Ca 2ϩ /Mg 2ϩ , binding occurred with a k on of 0.01 nM Ϫ1 min Ϫ1 , reaching equilibrium within 10 min, and dissociation was rapid, with a k off of 0.24 min Ϫ1 , resulting in a K D of 18 nM (Fig. 8B) . Because the saturation binding curves measured titration of the receptor to full occupancy, the K D values obtained from the kinetic binding curves represent the actual binding affinity. Although binding of the protein ligand 125 I-VCAM-Ig requires an activated state of ␣ 4 ␤ 1 , achieved by adding 1 mM Mn 2ϩ , 35 S-compound 1 is observed to bind both activated and unactivated states of ␣ 4 ␤ 1 . Although similar association rates were observed for the binding of 35 S-compound 1 to unactivated and activated ␣ 4 ␤ 1 , dissociation rates were dependent on the activation state of the integrin, with dissociation from the activated receptor indiscernible under the conditions of the assay. (Table 1) . Compound 2, a recently described ␣ 4 ␤ 1 antagonist (Hagmann et al., 2001) , and compound 3, a structurally related analog, inhibited binding to both ␣ 4 ␤ 1 and ␣ 4 ␤ 7 (Table 1 ). An inactive analog, compound 4 (Hagmann et al., 2001; Egger et al., 2002) , did not inhibit binding when tested at concentrations up to 100 M, demonstrating the importance of specific structural features to the activities of compounds 1, 2, and 3 (Kopka et al., 2002;  Table 1 ). TR14035 (Fig. 1) has been reported to potently inhibit both ␣ 4 ␤ 1 and ␣ 4 ␤ 7 Sircar et al., 1999a,b; Egger et al., 2002) , and this was confirmed (Table 1) .
After evaluating the potency of compounds in conventional ␣ 4 -ligand binding assays, we determined the potency of the same four compounds to block 35 S-compound 1 binding to RPMI-8866 cells in the presence of Mn 2ϩ and 100 nM BIO7662. The concentration of 35 S-compound 1 used for the binding assay was maintained at less than 150 pM, based on an IC 50 of 400 pM for competition by unlabeled compound 1 (Table 1) , and the results for the compounds tested are shown in Table 1 . Although a small (5-fold or less) shift toward reduced potency in the 35 S-compound 1/␣ 4 ␤ 7 assay was observed, a similar rank order of compounds (cmpd 1 Ն TR14035 Ͼ cmpd 2 Ͼ cmpd 3 Ͼ Ͼ cmpd 4) was maintained for the IC 50 values when the 35 S-compound 1/␣ 4 ␤ 7 and 125 IMAdCAM-Ig/␣ 4 ␤ 7 binding assays were compared.
The ability of the same four compounds to block 35 S-compound 1 binding to Jurkat cells expressing activated ␣ 4 ␤ 1 in A, specific binding (cpm) for compound association (f) to or dissociation (OE) from Mn 2ϩ -activated ␣ 4 ␤ 1 was measured as described under Materials and Methods. B, specific binding (cpm) for compound association (Ⅺ) to or dissociation (‚) from unactivated ␣ 4 ␤ 1 was measured as outlined above and as described under Materials and Methods. k obs was determined at a ligand concentration of 11.5 nM, and the on rate (k on ), off rate (k off ) and K D values for the binding of 35 S-compound 1 were determined from kinetic measurements by fitting the data to a one-phase exponential association or decay equation (R 2 value of 0.86 and 0.99 for association and dissociation, respectively). The data shown are representative of at least two independent experiments containing duplicate values in each experiment. (Table 1) . Nonselective compounds, those that have relatively equal potency for activated and unactivated ␣ 4 ␤ 1 , would be expected to follow the same rank order in both assays. Using this criterion, compounds 2 and 3 were identified as dual antagonists that are nonselective for ␣ 4 ␤ 1 , whereas TR14035 had a 17-fold greater potency for inhibiting binding to activated ␣ 4 ␤ 1 than for unactivated ␣ 4 ␤ 1 , making it a dual antagonist that is selective for activated ␣ 4 ␤ 1 .
Discussion
35 S-Compound 1 was used as a model ligand to study divergent ␣ 4 ␤ 7 -and ␣ 4 ␤ 1 -ligand interactions in the presence of different metal cations.
35 S-Compound 1 bound both unactivated and activated states of ␣ 4 ␤ 1 that occur in suspension in the presence of Ca 2ϩ /Mg 2ϩ or Mn 2ϩ , respectively, but only bound activated ␣ 4 ␤ 7 . Binding kinetics revealed that 35 S-compound 1 dissociated from activated ␣ 4 ␤ 7 and unactivated ␣ 4 ␤ 1 , but failed to dissociate from activated ␣ 4 ␤ 1 in the time frame observed. Although radiolabeled probes have been used to study the function of ␣ 4 ␤ 1 -ligand interactions (Chen et al., 1999 , this is the first report that a dual ␣ 4 ␤ 1 /␣ 4 ␤ 7 antagonist can be used to elucidate the effect of divalent cations on both ␣ 4 ␤ 7 -and ␣ 4 ␤ 1 -ligand interactions, defining distinct binding properties of the probe for each integrin.
Integrins are known to exist in multiple affinity states in the presence of different divalent cations (Shimaoka et al., 2002) . For many integrin-ligand interactions, including those of ␤ 1 , ␤ 2 , and ␤ 3 integrins, the most efficient binding to immobilized ligand occurs in the presence of Mn 2ϩ , with less binding in the presence of Mg 2ϩ , and little or no binding in the presence of Ca 2ϩ (Dransfield et al., 1992; Mould et al., 1995; Chen et al., 1999; Chigaev et al., 2001 (Higgins et al., 1998 (Fig. 3A with BIO7662 ). Mn 2ϩ enhanced the binding of 35 S-compound 1 to ␣ 4 ␤ 7 with an EC 50 of 0.5 mM (Fig. 6A) , whereas 1 mM Ca 2ϩ /Mg 2ϩ supported binding to ␣ 4 ␤ 1 , but not ␣ 4 ␤ 7 (Figs. 3A and 7B) . Ca 2ϩ alone did not support binding to ␣ 4 ␤ 7 , and nonphysiological levels of Mg 2ϩ were required to stimulate binding to ␣ 4 ␤ 7 (Fig. 6A) .
The 29% reduction in the binding of compound 1 to RPMI-8866 cells in Mn 2ϩ with 100 nM BIO7662 (Fig. 3A) added was surprising, because only a 5 to 10% drop in total counts bound was expected due to the binding to ␣ 4 ␤ 1 (Fig. 2A) . One explanation for this finding is that with 100 nM BIO7662 added, a small fraction of the ␣ 4 ␤ 7 was occupied by BIO7662 and blocked binding of 35 S-compound 1. To test this possibility, we reevaluated the binding of BIO7662 to ␣ 4 ␤ 7 , but on JY cells, a human B cell line, which expresses high levels of ␣ 4 ␤ 7 and no detectible ␣ 4 ␤ 1 . First, binding was evaluated using radiolabeled BIO7662. No specific measurable binding was observed with 10 nM 35 S-BIO7662, supporting the observation that the affinity of BIO7662 for ␣ 4 ␤ 7 is low. Second, the IC 50 of BIO7662 for ␣ 4 ␤ 7 was measured in an adhesion format in which the ability of BIO7662 to block binding of fluorescently labeled JY cells to plates coated with N- [4-(6- (Pepinsky et al., 2002) , an analog of compound 1 that had been engineered to contain a linker for cross-linking, was used for these studies. IC 50 values in this assay of 10 M in 1 mM Ca 2ϩ /Mg 2ϩ buffer and 1 M in 1 mM Mn 2ϩ verify that BIO7662 is a poor inhibitor of ␣ 4 ␤ 7 . Although these studies support the integrin selectivity data for BIO7662, the separation under activating conditions between the IC 50 of BIO7662 in the adhesion assay (1 M) and the amount added to prevent ␣ 4 ␤ 1 binding, 100 nM, was not as great as was predicted from the MAdCAM-Ig binding study (Table 1) , and consequently binding of BIO7662 to ␣ 4 ␤ 7 is likely to have accounted for the reduction in the counts bound for 35 S-compound 1. The RPMI-8866 cell line has been widely used in binding assays to identify ␣ 4 ␤ 7 antagonists (Carson et al., 1997; Shroff et al., 1998; Martin et al., 1999; Harriman et al., 2000) . We provide the first evidence that low levels of unactivated ␣ 4 ␤ 1 expressed on RPMI-8866 cells are capable of binding to a small molecule antagonist, such as 35 S-compound 1, and we demonstrate that unactivated ␣ 4 ␤ 7 on a variety of cell lines does not bind 35 S-compound 1. Low levels of ␣ 4 ␤ 1 expressed on RPMI-8866 cells do not contribute to binding of MAdCAMIg, and the binding of MAdCAM-1 to cells in suspension expressing ␣ 4 ␤ 7 is known to require Mn 2ϩ . Blockade of ␣ 4 ␤ 1 by BIO7662 abrogated binding of 35 S-compound 1 to RPMI-8866, K562/␣ 4 ␤ 7 , or HUT-78 cells in Ca 2ϩ /Mg 2ϩ , indicating that ␣ 4 ␤ 1 was responsible for binding observed in the unactivated condition (Fig. 3) . Thus, the binding properties of ␣ 4 integrins coexpressed on the same cell varies depending on the state of activation.
Recent reports have described the use of radiolabeled small molecule ligands that can be used to study ␣ 4 ␤ 1 -ligand interactions (Chen et al., 1999 ). For example, 35 S-BIO7662 is a specific ␣ 4 ␤ 1 antagonist that binds with high affinity (K D Ͻ 10 pM) to both unactivated and activated ␣ 4 ␤ 1 . Solution binding studies on purified ␣ 4 ␤ 1 identified a high-affinity site for Ca 2ϩ that stimulates BIO7662 binding and a low-affinity site that functions independently of BIO7662 binding ). Similarly, [
3 H]BIO1211 has been identified as a specific ␣ 4 ␤ 1 antagonist that binds with low affinity (K D of 20 -40 nM) to unactivated ␣ 4 ␤ 1 but with high affinity to activated ␣ 4 ␤ 1 (K D of 18 -100 pM) to Chen et al. (1999) . Studies with antagonists of ␣ 4 ␤ 1 demonstrate that the metal ion dependence of ligand binding is affected by the affinity of the ligand for ␣ 4 ␤ 1 , because the ED 50 concentrations required to support BIO7662 binding were 2-fold lower for Mn 2ϩ , 30-fold lower for Mg 2ϩ , and Ͼ1000-fold lower for Ca 2ϩ , compared with the concentrations required to support BIO1211 binding (Chen et al., 1999 .
Compared with association rates reported for BIO7662, BIO1211 and an LDV-based peptide, the association rate for compound 1 binding to ␣ 4 ␤ 1 in the presence of 1 mM Ca 2ϩ / Mg 2ϩ was greater by an order of magnitude (Chen et al., 1999 Chigaev et al., 2001) . Consistent with published reports on the binding properties of specific ␣ 4 ␤ 1 antagonists, 35 S-compound 1 had similar association rates for binding to unactivated and activated ␣ 4 ␤ 1 , but dissociation rates were highly dependent on the state of activation (Fig. 8) .
35 SCompound 1 rapidly dissociated from Jurkat cells expressing unactivated ␣ 4 ␤ 1 , but dissociation from activated ␣ 4 ␤ 1 could not be observed even after 180 min. Although 35 S-compound 1 is a lower affinity ligand than BIO1211 or BIO7662, this is the first report of a dual ␣ 4 ␤ 1 /␣ 4 ␤ 7 antagonist that can be used to study the metal-cation dependence of both ␣ 4 ␤ 1 and ␣ 4 ␤ 7 binding.
Finally, observations presented here have key implications for the development of a dual ␣ 4 ␤ 1 /␣ 4 ␤ 7 antagonist that is selective or nonselective for ␣ 4 ␤ 1 . Both ␣ 4 ␤ 1 and ␣ 4 ␤ 7 are pharmaceutical targets for a variety of inflammatory disorders, including asthma, inflammatory bowel disease, and multiple sclerosis (Gordon et al., 2001; Jackson, 2002) . The two ␣ 4 integrins are unique in their ability to act both as low-affinity receptors that participate in rolling and tethering, and as high-affinity receptors that mediate firm adhesion Berlin et al., 1995) . A continuum of integrin activation states is known to exist in vivo, and the Mn 2ϩ -activated state may not resemble the highest affinity state that occurs under physiological conditions. Integrin activation through G protein-linked receptors occurs within seconds, whereas activation-dependent arrest takes minutes (Butcher, 1999) . Because the association rate of an antagonist may be slower than the rate of integrin activation, a nonselective antagonist may be required for effective blockade of ligand binding, and nonselective neutralizing antibodies against ␣ 4 and ␣ 4 ␤ 7 are known to be efficacious in in vivo models (Foster, 1996; Butcher, 1999) . Both a selective antagonist that blocks binding to the activated state or a nonselective antagonist will inhibit the extravasation of lymphocytes to extracellular sites. Access to integrins after they bind high-affinity ligands, however, may be limited, or it may be too late to disrupt tight binding, and a nonselective antagonist might overcome this problem.
State-selective antagonists of ␣ 4 ␤ 1 , however, may have an improved embryonic safety profile. Microinjection of a nonselective ␣ 4 ␤ 1 blocking antibody or continuous exposure of rat whole embryo cultures to nonselective antagonists of ␣ 4 ␤ 1 can induce defects in chorio-allantoic fusion. Although a selective antagonist of ␣ 4 ␤ 1 was evaluated in this study, the lack of potency of this compound in 90% serum made it difficult to assess the role of selective antagonism on development (Spence et al., 2002) . Furthermore, although gene knockouts of the ␣ 4 subunit or VCAM-1 have been shown to result in embryo-lethality, this is not the case for gene knockouts of ␤ 7 (Butcher, 1999) . Thus, the use of small molecule ligands to measure binding parameters of ␣ 4 ␤ 1 and ␣ 4 ␤ 7 in different states of activation will advance our understanding of how to develop potent, efficacious, and safe antagonists of ␣ 4 ␤ 1 and ␣ 4 ␤ 7 .
